Brooks-LaSure Poised to be Confirmed as CMS Administrator

The U.S. Senate is expected today to approve Chiquita Brooks-LaSure's nomination to be CMS Administrator.

The U.S. Senate is expected today to confirm Chiquita Brooks-LaSure’s nomination to be Administrator of the Centers for Medicare & Medicaid Services (CMS), clearing the way for the swearing in of another key Biden administration official with influence touching on

Read More »

Breaking News

BREAKING: Developments in Multiple 340B Contract Pharmacy Lawsuits

Eli Lilly and Sanofi yesterday filed court papers in response to HRSA's 340B contract cease and desist letters. Novo Nordisk is expected to follow suit. There could be a decision on AstraZeneca's motions as soon as tonight. | Shutterstock

Drug manufacturers Eli Lilly and Sanofi late yesterday asked federal judges for temporary protection from federal health agency orders to immediately resume offering 340B pricing on drugs shipped to contract pharmacies. Drug maker Novo Nordisk is expected to seek similar

Read More »

BREAKING: Developments in AstraZeneca’s 340B Lawsuit

AstraZeneca and the federal government are miles apart on what a federal judge should do next in the company's 340B contract pharmacy lawsuit.

A federal district judge in Wilmington, Del., this morning gave the federal government until 11:00 a.m. Eastern tomorrow to respond to AstraZeneca’s emergency motion yesterday for a stay in its lawsuit over the government’s efforts to compel it to resume

Read More »

Drugmakers Show No Sign So Far of Giving in to HRSA on 340B Contract Pharmacy

So far, drug manufacturers have shown no sign of obeying HRSA's order to resume 340B pricing without regard to how drugs are dispensed. | Shutterstock

Six drug companies have shown no sign so far of acquiescing to the federal government’s order on Monday to immediately resume 340B pricing on their products dispensed by contract pharmacies.

340B covered entities yesterday reported seeing no evidence that Eli

Read More »

Health Centers, HIV/AIDS Clinics, and Feds Agree on Keeping Stays in Place in 340B Lawsuits

In separate status reports to a federal judge last night, health centers and the government, and HIV/AIDS clinics and the government, agreed to keep stays in place in lawsuits involving 340B contract pharmacy. | Shutterstock

The National Association of Community Health Centers (NACHC) and the U.S. Justice Department (DOJ) last night proposed that a federal district judge should maintain the stay in NACHC’s suit against the government stemming from drug manufacturers’ denials of 340B pricing

Read More »

Year 2 of 340B Contract Pharmacy Fight Starts With a Bang

HRSA's cease and desist letters to six drug manufacturers likely ensures that this will be another explosive year for 340B contract pharmacy. | Shutterstock

Today is the anniversary of Eli Lilly lighting the fuse on the 340B program’s most explosive year ever.

On May 18, 2020, Lilly sent the U.S. Health Resources and Services Administration (HRSA) a letter saying that, unless it heard otherwise

Read More »

Drug Makers Defensive, Providers Thrilled About HRSA’s 340B Contract Pharmacy Letters

"Today is the day we’ve been waiting for," RWC-340B President Shannon Stephenson said about HRSA's 340B contract cease and desist letters yesterday to six drug manufacturers.

Drug manufacturers yesterday defended the legality of their restrictions on 340B contract pharmacy, in the wake of cease and desist letters from the U.S. Health Resources and Services Administration (HRSA).

Groups and individuals representing 340B covered entities, meanwhile, praised HRSA

Read More »

Breaking News

BREAKING: HRSA to Six Drug Makers—Your 340B Contract Pharmacy Policies Are Illegal, Resume Offering 340B Pricing Immediately

HRSA Acting Administrator Diana Espinosa sent letters this morning to six drug manufacturers telling them their 340B contract pharmacy policies are illegal and must be stopped immediately.

U.S. Health Resources and Services Administration (HRSA) Acting Administrator Diana Espinosa this morning informed six pharmaceutical manufacturers that their restrictions on 340B program pricing to covered entities that dispense medications through contract pharmacies have resulted in overcharges and are in

Read More »

DOJ Cites 1996 HRSA Letter to PhRMA in Request to Dismiss Novo Nordisk’s 340B Contract Pharmacy Suit

DOJ says Novo Nordisk’s claim that HHS's 340B contract pharmacy advisory opinion would make it break the law “is mere legerdemain.”

Novo Nordisk’s claim that a federal legal advisory opinion on 340B contract pharmacy would make it unlawfully transfer its drugs to ineligible pharmacies and ineligible patients “is mere legerdemain” (slight of hand), government lawyers for U.S. Health and Human Services

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report